Ovid Therapeutics Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDOvid Therapeutics Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings contraction of 64% provides fundamental context to the price action. Investors should exercise caution due to high volatility (113% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.39 | +13.64% | ABOVE |
| 50 SMA | $2.57 | +5.81% | ABOVE |
| 100 SMA | $2.30 | +18.24% | ABOVE |
| 150 SMA | $2.07 | +31.13% | ABOVE |
| 200 SMA | $1.92 | +41.95% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is OVID in an uptrend right now?
OVID has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, OVID is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is OVID overbought or oversold?
OVID's RSI (14) is 55. The stock is in neutral territory, neither overbought nor oversold.
Is OVID outperforming the market?
OVID has a Relative Strength (RS) Rating of 89 out of 99. Yes, OVID is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is OVID in its 52-week range?
OVID is trading at $2.72, which is 88% of its 52-week high ($3.10) and 86% above its 52-week low ($0.30).
How volatile is OVID?
OVID has a Beta of 1.21 and 52-week volatility of 113%. It's more volatile than the S&P 500 - expect bigger swings.